BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35500065)

  • 1. MicroRNA profiling predicts positive nodal status in papillary thyroid carcinoma in the preoperative setting.
    Napoli F; Rapa I; Mortara U; Massa F; Izzo S; Rigutto A; Zambelli V; Bellevicine C; Troncone G; Papotti M; Volante M
    Cancer Cytopathol; 2022 Sep; 130(9):695-704. PubMed ID: 35500065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyto-Histological Profile of MicroRNAs as Diagnostic Biomarkers in Differentiated Thyroid Carcinomas.
    Matos ML; Pinto M; Alves M; Canberk S; Gonçalves A; Bugalho MJ; Papoila AL; Soares P
    Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF mutation, selected miRNAs and genes expression in primary papillary thyroid carcinomas and local lymph node metastases.
    Kalfert D; Ludvikova M; Pesta M; Hakala T; Dostalova L; Grundmannova H; Windrichova J; Houfkova K; Knizkova T; Ludvik J; Polivka J; Kholova I
    Pathol Res Pract; 2024 Jun; 258():155319. PubMed ID: 38696857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant expression of five miRNAs in papillary thyroid carcinomas.
    Qiao DH; He XM; Deng X; Ji YC; Yang H; Cheng L; Zhou XY
    J Clin Lab Anal; 2021 Sep; 35(9):e23907. PubMed ID: 34268792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping the Molecular Basis and Markers of Papillary Thyroid Carcinoma Progression and Metastasis Using Global Transcriptome and microRNA Profiling.
    Akyay OZ; Gov E; Kenar H; Arga KY; Selek A; Tarkun İ; Canturk Z; Cetinarslan B; Gurbuz Y; Sahin B
    OMICS; 2020 Mar; 24(3):148-159. PubMed ID: 32073999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas.
    Dettmer M; Vogetseder A; Durso MB; Moch H; Komminoth P; Perren A; Nikiforov YE; Nikiforova MN
    J Clin Endocrinol Metab; 2013 Jan; 98(1):E1-7. PubMed ID: 23150679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.
    Dettmer M; Perren A; Moch H; Komminoth P; Nikiforov YE; Nikiforova MN
    Thyroid; 2013 Nov; 23(11):1383-9. PubMed ID: 23427895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling.
    Galuppini F; Censi S; Merante Boschin I; Fassan M; Sbaraglia M; Valeri N; Hahne JC; Bertazza L; Munari G; Galasso M; Cascione L; Barollo S; Rugge M; Vianello F; Dei Tos AP; Mian C; Pennelli G
    Front Endocrinol (Lausanne); 2022; 13():834075. PubMed ID: 35282462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNAs miR-146-5p and let-7f as prognostic tools for aggressive papillary thyroid carcinoma: a case report.
    Geraldo MV; Fuziwara CS; Friguglieti CU; Costa RB; Kulcsar MA; Yamashita AS; Kimura ET
    Arq Bras Endocrinol Metabol; 2012 Nov; 56(8):552-7. PubMed ID: 23295297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.
    Geraldo MV; Nakaya HI; Kimura ET
    Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma.
    Yip L; Kelly L; Shuai Y; Armstrong MJ; Nikiforov YE; Carty SE; Nikiforova MN
    Ann Surg Oncol; 2011 Jul; 18(7):2035-41. PubMed ID: 21537871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of miR-7-5p and miR-548ar-5p predicts malignancy in indeterminate thyroid nodules negative for BRAF and RAS mutations.
    Macerola E; Poma AM; Proietti A; Rago T; Romani R; Vignali P; Ugolini C; Torregrossa L; Basolo A; Santini F; Basolo F
    Endocrine; 2022 Jun; 76(3):677-686. PubMed ID: 35347579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
    Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
    BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating microRNA124-3p, microRNA9-3p and microRNA196b-5p may be potential signatures for differential diagnosis of thyroid nodules.
    Yu S; Liu X; Zhang Y; Li J; Chen S; Zheng H; Reng R; Zhang C; Chen J; Chen L
    Oncotarget; 2016 Dec; 7(51):84165-84177. PubMed ID: 27705935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma.
    Qiu Z; Li H; Wang J; Sun C
    Oncol Rep; 2017 Nov; 38(5):2735-2740. PubMed ID: 29048684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression profile and clinical significance of microRNAs in papillary thyroid carcinoma.
    Peng Y; Li C; Luo DC; Ding JW; Zhang W; Pan G
    Molecules; 2014 Aug; 19(8):11586-99. PubMed ID: 25100252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors.
    Titov SE; Ivanov MK; Karpinskaya EV; Tsivlikova EV; Shevchenko SP; Veryaskina YA; Akhmerova LG; Poloz TL; Klimova OA; Gulyaeva LF; Zhimulev IF; Kolesnikov NN
    BMC Cancer; 2016 Mar; 16():201. PubMed ID: 26960768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features.
    Jahanbani I; Al-Abdallah A; Ali RH; Al-Brahim N; Mojiminiyi O
    Thyroid; 2018 Mar; 28(3):319-327. PubMed ID: 29378472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.